Mountain View, CA – According to filings with the U.S. Securities and Exchange Commission, Amunix Pharmaceuticals is raising $2,579,360.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Angie You played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amunix Pharmaceuticals

At Amunix, we are focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. Since our founding in 2006, we have operated as a technology licensing company, forging agreements with multiple leading biopharmaceutical companies such as Roche, Merck, Celgene, and Biogen, to leverage XTEN, a proprietary half-life extension technology, and Pro-XTEN, a next-generation prodrug technology.

To learn more about Amunix Pharmaceuticals, visit http://www.amunix.com/

Contact:
Angie You, Chief Executive Officer
650-428-1800
ayou@amunix.com
https://www.linkedin.com/in/angie-you-5961111/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved